About Us A top Japan-based generic manufacturer.

Corporate HistoryCorporate Information

History of Nichi-Iko

History of Nichi-Iko


To mark the 50th anniversary of Nichi-Iko Pharmaceutical on July 15, 2015, we captured the essence of the company history and challenges for the future in a short animation video. Watch history of Nichi-Iko, the relentless pursuer of “Premium Quality”.

1965
  • ・Nihon Iyakuhin Kogyo Co., Ltd. established
1967
  • ・Completed the plant to produce pharmaceutical tablets and powder in Toyama City, followed by the completion of the plant to produce injection drugs.
1970
  • ・Completed Namerikawa Plant in Namerikawa City
1972
  • ・Completed Research Institute on Toyama Plant premises
1974
  • ・Completed Head Office Building in Sogawa, Toyama City
1980
  • ・Listed on Nagoya Stock Exchange, Second Section
1981
  • ・Listed on Osaka Stock Exchange, Second Section
1983
  • ・Completed new GLP-compliant Research Institute adjacent to Namerikawa Plant
1985
  • ・Established Tokyo Branch Office Building in Bunkyo Ward, Tokyo
1986
  • ・Completed Fukuno Plant (now Nanto) in Fukunomachi, Higashi Tonamigun, Toyama Prefecture
1987
  • ・Launched SEDAPAIN Injection as new proprietary drug, a central nervous system analgesic
1993
  • ・Launched CADEX, a drug to treat pressure ulcer and skin ulcer under foreign license was obtained
1994
  • ・LaucnchedUNICON Tablets, a drug to treat asthma diseases under foreign license
1995
  • ・Established Head Office Annex as the 30th anniversary of company's foundation
1996
  • ・Completed revised GMP-compliant injection plant in Yasuda, Namerikawa City
1997
  • ・Adopted new GPMSP-compliant corporate framework
1998
  • ・Adopted new GCP-compliant corporate framework
2000
  • ・Established MPS (Medical Practice Support) team at all business offices
2001
  • ・Made partially acquisition of OTC business from Japan Tobacco, Inc.
  • ・Launched FERRUM Capsules, slow-release iron preparation for oral use and synthetic penicillin PENGOOD as Branded Generic Drug.
2003
  • ・Completed Nichi-Iko Distribution Center in Namerikawa City
  • ・Launched FESIN Injection, iron preparation for I.V. use as Branded Generic Drug.
2004
  • ・Installed new sales support system in the Sales Division.
  • ・Acquired the sales operation right of Maruko Pharmaceutical Co., Ltd.
2005
  • ・Merged Nihon-Gallen Co., Ltd.
  • ・Acquired partially the stock of Maruko Pharmaceutical Co., Ltd., who was subsequently the subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.
  • ・Changed the company name to Nichi-Iko Co., Ltd.(the official registered name in English :Nichi-Iko Pharmaceutical Co., Ltd.)
  • ・Acquired partially the stock of Oriental Pharmaceutical Co., Ltd., who was subsequently the subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.
2006
  • ・Completed Pharmaceutical Development Center adjacent to Namerikawa Plant
  • ・Commenced the operation of Higashi-Nihon Distribution Center
  • ・Promoted to First Section of both Osaka Stock Exchange and Nagoya Stock Exchange
2007
  • ・Merged with Maruko Pharmaceutical Co., Ltd. to be the wholly owned subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.
  • ・Dissolved Kobayashi Yakugaku Industry Co., Ltd., one of the subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.
2008
  • ・Merged and Aquired Teikoku Medix Co., Ltd., to be wholly owned subisidiary of Nichi-iko Pharmaceutical Co., Ltd.
2009
  • ・Maruko Pharmaceutical Co., Ltd., Oriental Pharmaceutical Co., Ltd., and Teikoku Medix Co., Ltd. were consolidated to create Nichi-iko Pharma Factory Co., Ltd.
  • ・Active Pharma Co., Ltd., a manufacturer of Apls for generics, was created as a joint venture company with Mitani Sangyo Co., Ltd.
2010
  • ・Remodeled flagship plant "Pentagon" in Namerikawa city, Toyama started full operation.
  • ・Established sanofi-aventis Nichi-Iko K.K. by joint capital investment with sanofi-aventis Group (Currently SANOFI)
  • ・Entered into Full Agency Agreement regarding marketing, sales, distribution and logistics in Hong Kong, Thailand and Malayshia with DKSH.
  • ・Entered into a capital and business alliance agreement with Aprogen Inc. for research and development of biosimilar products.
  • ・Listed on the Tokyo Stock Exchange, First Section.
2011
  • ・Establishment of Nichi-Iko Medical Practice Institute Co., Ltd.
  • ・Completed Global Development center, Honeycomb building.
  • ・Delisting from Osaka Stock Exchange and Nagoya Stock Exchange
2012
  • ・Announced the 6th Medium term business plan "Pyramid"
  • ・Acquired Yakuhan Pharmaceutical Co., Ltd.
  • ・Merger consolidated subsidiary, Nichi-Iko Pharmaceutical Co., Ltd.
  • ・Tokyo office became another head quarter and Namerikawa Plant 1& 2 renamed Toyama Plant 1& 2.
2013
  • ・Completed 2nd flagship plant "Pyramid" in Namerikawa city.
  • ・Merged and Aquired Yakuhan Pharmaceutical Co., Ltd., to be wholly owned subisidiary of Nichi-iko Pharmaceutical Co., Ltd.
  • ・Established Nichi-Iko Bangkok Representative Office in Thailand
  • ・Entered into a business alliance with Biolab in Thailand
  • ・Entered into a basic agreement for business acquisition of Astellas Pharma Group, Fuji Plant
  • ・Entered into an agreement for capital alliance with Binex in Korea
  • ・Entered into a business alliance with Hanoi Pharma in Vietnam
  • ・Issued the Commitment-type Rights Offering (Allotment of Listing-type Stock Acquisition Rights without Contribution)
2014
  • ・Established Nichi-Iko (Thailand) Co., Ltd. as a 100% owned local subsidiary in Thailand
  • ・Established NIXS Corporation as a 100% owned local subsidiary in USA
  • ・Launched Nichi-Iko Pharma Tech Co., Ltd. as a consolidated subsidiary
2015
  • ・Entered into a business alliance with Bangkok Lab and Cosmetic in Thailand
2016
  • ・Announced the 7th Medium term business plan "Obelisk"
  • ・Acquired all outstanding stocks of Sagent Pharmaceuticals, Inc.
    and made it a wholly owned subsidiary.
2017
  • ・Obtained Marketing Approval for infliximab BS for I.V.Infusion 100mg "Nichi-Iko"
  • ・Merger consolidated subsidiary, Nichi-Iko Pharma Tech Co., Ltd.

Back to Top